Mesoblast shares up following FDA tick for phase II trials
31 January, 2012 by Tim DeanThe US Food and Drug Administration has given the go-ahead for Mesoblast (ASX:MSB) to conduct phase II trials of its stem cell treatment for Type 2 diabetes.
Last chance to take part in AusBiotech’s annual CEO survey
31 January, 2012 by AusBiotechWith the annual CEO Industry Position Survey 2012 closing this week, AusBiotech urges industry leaders to take this opportunity to contribute to the research, enabling an updated and comprehensive view of the Australian biotechnology sector.
Australian-French partnership team up for drug development
30 January, 2012 by Dylan Bushell-EmblingThe Monash Institute of Pharmaceutical Sciences and France's Servier have entered a three-year partnership for drug development research into G Protein-Coupled Receptors.
A promise to a dying friend turns to a quest for a cure
27 January, 2012 by AusBiotechIt began with a promise to a dying friend and became a dedicated quest for a cure for cancer ... and a fundraiser to help.
Xenome raises soothing $8m for pain treatment trial
27 January, 2012 by Dylan Bushell-EmblingBrisbane-based biopharma Xenome Limited has secured $8m in funding from its major investors to pay for a clinical trial of a synthetic peptide as a pain inhibitor.
Biosceptre seeks $15m for anti-cancer monoclonal antibody trials
24 January, 2012 by Tim DeanFunds sought to take monoclonal antibody treatment for multiple cancers into phase I trials on the lead up to IND submission with the US Food and Drug Administration.
BioProspect tightens its focus
24 January, 2012 by Dylan Bushell-EmblingAfter suffering two costly delays, BioProspect (ASX:BPO) is refocusing on gaining local regulatory approval for its lead animal health product.
Australian biotechs attract strong interest at US investor meeting
23 January, 2012 by AusBiotechThe latest AusBiotech investor showcase event in the US has attracted its strongest attendance yet, with the presentations from the participating Australian companies and networking well received.
Sienna signs licensing deal for cancer test
23 January, 2012 by Dylan Bushell-EmblingSienna Cancer Diagnostics has reached a new agreement with licensor Geron for the IP needed to continue development its telomerase protein detector tests.
Chardonnay genome project seeks to improve wine
20 January, 2012 by Tim DeanA joint effort by the Australian Wine Research Institute and the University of British Columbia will sequence 15 varieties of the world’s most popular wine grape.
vivoPharm signs oncology partner for US
19 January, 2012 by Dylan Bushell-EmblingSouth Australia's vivoPharm has arranged to co-market primary patient-derived tumours owned by Berlin's EPO to US cancer drug researchers.
Comment sought on "Enabling Technologies Roadmap"
19 January, 2012 by AusBiotechThe government is seeking comment on a new report covering the future of biotechnology and nanotechnology.
UQ, industry partner for rheumatoid arthritis treatment
18 January, 2012 by Dylan Bushell-EmblingUniQuest spinoff and pharmaceutical R&D company Janssen-Cilag will combine resources to support the development of a rheumatoid arthritis treatment.
Clinuvel trading at nine-month highs
17 January, 2012 by Dylan Bushell-EmblingClinuvel Pharmaceuticals’ (ASX:CUV) cites positive trial results for SCENESSE as likely reason for 34.2% spike in stock price last week.
Industry leaders to take part in annual industry position survey
17 January, 2012 by AusBiotechAusBiotech is pleased to once again conduct the annual CEO Industry Position Survey 2012, this year proudly supported by Grant Thornton.
